Volume 12, Number 8—August 2006

Dispatch

Changing Pattern of Visceral Leishmaniasis, United Kingdom, 1985-2004

Aeesha N.J. Malik*, Lawrence John*, Anthony D.M. Bryceson*, and Diana N.J. Lockwood* 

Author affiliations: *Hospital for Tropical Diseases, London, United Kingdom

Main Article

Figure 2

Figure 2. Initial drug treatment for patients with visceral leishmaniasis and number of relapses. Na stibo, stibogluconate; Meg, meglumine antimoniate; Paro, paromomycin; Pent, pentamidine; Amb, ambisome; Amp, amphotericin.

Main Article

Top of Page

The opinions expressed by authors contributing to this journal do not necessarily reflect the opinions of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.